Whitelab Genomics to Present on AI-Driven Advances in Genomic Medicine at ESGCT 2024

From its founding, Whitelab Genomics has leveraged AI to transform the field of genomic medicine. Based on exhaustive datasets, the platform provides in-silico simulations to streamline the design and optimization of AAV vectors, significantly reducing development timelines while enhancing targeting specificity. By harnessing these innovations, Whitelab Genomics aims to unlock the full potential of genomic medicine.

At the ESGCT Congress, Whitelab Genomics will share key insights from its AI-driven research on AAV vector design and LNP small molecule discovery, showcasing how these advances can accelerate the creation of effective therapies. This conference will provide an opportunity to discuss the broader impact of machine learning in genomic medicine, highlighting real-world applications and the challenges faced when using AI to drive precision in drug design.

P0065 – Tuesday 22, 19:30 - 21:00
Title: Optimizing AAV Vectors for Precision Gene Therapy: A Rational Design Approach
Presenter: Claire Colas

P0190 – Wednesday 23, 13:30 - 15:00
Title: Integration of Protein Language Models and Reinforcement Learning for the Systematic Design of Phenotype-Specific AAV Capsids
Presenter: Oscar De Felice

P0927 – Thursday 24, 14:00 - 15:30
Title: Novel In Silico Protocol for Small Molecule Discovery Enhancing Lipid Nanoparticle Targeting Specificity
Presenter: Bryan Dafniet

P0842 – Thursday 24, 18:00 - 19:30
Title: An Enhanced Protein Language Model for Cell Surface Protein Identification in Genomic Therapies
Presenter: Chloé Canavate

For those interested in learning more about our innovative projects, we invite you to schedule a meeting with our team:
Timothé Cynober, Head of BD & Licensing
Rayhan Ullah, BD Associate

Founded in 2019, backed by Y-Combinator, WhiteLab Genomics stands at the convergence of computer sciences and biology, pioneering the accelerated development of genomic medicines. By leveraging their proprietary technology, WhiteLab Genomics analyzes complex biological data powered by AI to significantly reduce development timelines and mitigate associated risks. Based on exhaustive datasets, the platform provides in-silico simulations to discover, and design optimized payloads and vectors. WhiteLab aims to expedite the drug development process, cut costs, and accelerate the delivery of life-saving therapies to the market. The company collaborates with leading pharmaceutical companies such as Sanofi, academic institutions, and innovative biotechnology companies. Recognized for their contribution to advancing the field of gene and cell therapy, WhiteLab Genomics is part of the prestigious French government supported French Tech 2030 program and recently joined the Bayer Co.Lab in Cambridge, MA, and Ginkgo Bioworks’ Technology Network, marking major milestones in our international expansion.